12.71 USD
+0.08 (+0.63%)
FTRE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. FTRE has a bad profitability rating. Also its financial health evaluation is rather negative. FTRE has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
FTRE had positive earnings in the past year.
In the past year FTRE had a positive cash flow from operations.
In multiple years FTRE reported negative net income over the last 5 years.
In the past 5 years FTRE always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -37.01%, FTRE is doing worse than 79.31% of the companies in the same industry.
FTRE has a worse Return On Equity (-174.74%) than 86.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| ROIC | N/A |
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 18.61%, FTRE is doing worse than 82.76% of the companies in the same industry.
FTRE's Gross Margin has been stable in the last couple of years.
FTRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
2. Health
2.1 Basic Checks
FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FTRE has been increased compared to 1 year ago.
Compared to 1 year ago, FTRE has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.56, we must say that FTRE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FTRE (0.56) is worse than 68.97% of its industry peers.
A Debt/Equity ratio of 1.81 is on the high side and indicates that FTRE has dependencies on debt financing.
FTRE has a worse Debt to Equity ratio (1.81) than 82.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.56 |
ROIC/WACCN/A
WACC10.66%
2.3 Liquidity
A Current Ratio of 1.00 indicates that FTRE should not have too much problems paying its short term obligations.
The Current ratio of FTRE (1.00) is worse than 89.66% of its industry peers.
FTRE has a Quick Ratio of 1.00. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
FTRE has a worse Quick ratio (1.00) than 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
FTRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.71%, which is quite impressive.
FTRE shows a decrease in Revenue. In the last year, the revenue decreased by -0.54%.
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%3.91%
3.2 Future
The Earnings Per Share is expected to grow by 32.18% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 2.57% on average over the next years.
EPS Next Y72.65%
EPS Next 2Y56.76%
EPS Next 3Y48.67%
EPS Next 5Y32.18%
Revenue Next Year-1.78%
Revenue Next 2Y-1.31%
Revenue Next 3Y0.1%
Revenue Next 5Y2.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
FTRE is valuated rather expensively with a Price/Earnings ratio of 24.92.
Based on the Price/Earnings ratio, FTRE is valued cheaply inside the industry as 81.03% of the companies are valued more expensively.
FTRE's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.31.
FTRE is valuated correctly with a Price/Forward Earnings ratio of 15.21.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FTRE indicates a rather cheap valuation: FTRE is cheaper than 94.83% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.56. FTRE is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.92 | ||
| Fwd PE | 15.21 |
4.2 Price Multiples
FTRE's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 179.31 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FTRE's earnings are expected to grow with 48.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y56.76%
EPS Next 3Y48.67%
5. Dividend
5.1 Amount
No dividends for FTRE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:FTRE (11/28/2025, 7:34:15 PM)
12.71
+0.08 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners112.28%
Inst Owner Change-4.62%
Ins Owners0.34%
Ins Owner Change25.38%
Market Cap1.17B
Revenue(TTM)2.76B
Net Income(TTM)-1.01B
Analysts53.75
Price Target10.56 (-16.92%)
Short Float %10.87%
Short Ratio7.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)88.02%
Min EPS beat(2)-21.52%
Max EPS beat(2)197.56%
EPS beat(4)2
Avg EPS beat(4)62.76%
Min EPS beat(4)-51.68%
Max EPS beat(4)197.56%
EPS beat(8)2
Avg EPS beat(8)-65.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.39%
Min Revenue beat(2)6.15%
Max Revenue beat(2)10.63%
Revenue beat(4)3
Avg Revenue beat(4)4.73%
Min Revenue beat(4)-2.83%
Max Revenue beat(4)10.63%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)35.29%
PT rev (3m)50%
EPS NQ rev (1m)-10.35%
EPS NQ rev (3m)-8.89%
EPS NY rev (1m)3.76%
EPS NY rev (3m)2.2%
Revenue NQ rev (1m)1.94%
Revenue NQ rev (3m)2.78%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)0.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.92 | ||
| Fwd PE | 15.21 | ||
| P/S | 0.43 | ||
| P/FCF | N/A | ||
| P/OCF | 782.93 | ||
| P/B | 2.02 | ||
| P/tB | N/A | ||
| EV/EBITDA | 179.31 |
EPS(TTM)0.51
EY4.01%
EPS(NY)0.84
Fwd EY6.57%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)0.02
OCFY0.13%
SpS29.87
BVpS6.29
TBVpS-10.96
PEG (NY)0.34
PEG (5Y)N/A
Graham Number8.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.61% | ||
| FCFM | N/A |
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score4
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 86.95 | ||
| Cap/Depr | 18.24% | ||
| Cap/Sales | 0.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 12.4% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1 | ||
| Quick Ratio | 1 | ||
| Altman-Z | 0.56 |
F-Score4
WACC10.66%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
EPS Next Y72.65%
EPS Next 2Y56.76%
EPS Next 3Y48.67%
EPS Next 5Y32.18%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%3.91%
Revenue Next Year-1.78%
Revenue Next 2Y-1.31%
Revenue Next 3Y0.1%
Revenue Next 5Y2.57%
EBIT growth 1Y22.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.82%
EBIT Next 3Y10.43%
EBIT Next 5Y10.01%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A
FORTREA HOLDINGS INC / FTRE FAQ
What is the ChartMill fundamental rating of FORTREA HOLDINGS INC (FTRE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to FTRE.
What is the valuation status of FORTREA HOLDINGS INC (FTRE) stock?
ChartMill assigns a valuation rating of 5 / 10 to FORTREA HOLDINGS INC (FTRE). This can be considered as Fairly Valued.
What is the profitability of FTRE stock?
FORTREA HOLDINGS INC (FTRE) has a profitability rating of 2 / 10.
What are the PE and PB ratios of FORTREA HOLDINGS INC (FTRE) stock?
The Price/Earnings (PE) ratio for FORTREA HOLDINGS INC (FTRE) is 24.92 and the Price/Book (PB) ratio is 2.02.
What is the expected EPS growth for FORTREA HOLDINGS INC (FTRE) stock?
The Earnings per Share (EPS) of FORTREA HOLDINGS INC (FTRE) is expected to grow by 72.65% in the next year.